Zobrazeno 1 - 10
of 433
pro vyhledávání: '"M, Andrejak"'
Autor:
M. Andrejak, Catherine Lok, O. Miquel-Christophe, D. Thuillier, E. Dascotte, Ali Dadban, Guillaume Chaby, D. Chatelain
Publikováno v:
Annales de Dermatologie et de Vénéréologie. 136:705-708
Resume Introduction La dermatose bulleuse hemorragique sous heparine est un effet indesirable de description recente. Nous rapportons un nouveau cas de cette toxidermie, survenue a distance des sites d’injection d’heparine de bas poids moleculair
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c7693f30e92559c2123c131ae54e38ea
https://doi.org/10.1016/j.annder.2008.10.037
https://doi.org/10.1016/j.annder.2008.10.037
Publikováno v:
Journal of Neurology. 255:1045-1048
Valvular heart abnormalities have been reported in patients with Parkinson's disease (PD) treated with pergolide. However, the incidence and severity of these abnormalities vary from study to study and their course after drug withdrawal has not been
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04b37a021f922b6bcbbe83bd719c762d
https://doi.org/10.1007/s00415-008-0839-1
https://doi.org/10.1007/s00415-008-0839-1
Autor:
V. Strunski, M. Andrejak, J.-P. Ducroix, S Outurquin, Amar Smail, B. Bénabès-Jezraoui, G. Chaby, V. Gras, V. Salle, C Lok
Publikováno v:
La Revue de Médecine Interne. 25:501-506
Resume Propos. – Les inhibiteurs d'enzyme de conversion de l'angiotensine (IEC) sont utilises depuis une vingtaine d'annees, et constituent un reel progres dans la prise en charge de l'hypertension arterielle ou de l'insuffisance cardiaque. Leur to
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c8e71978acd483edec0036b0e82d2d3
https://doi.org/10.1016/j.revmed.2004.02.024
https://doi.org/10.1016/j.revmed.2004.02.024
Autor:
J.-P. Denoeux, M. Andrejak, G. Chaby, V. Brenet-Dufour, R. Makdassi, Catherine Lok, O. Miquel
Publikováno v:
Annales de Dermatologie et de Vénéréologie. 134:855-857
Resume Introduction Le mycophenolate de sodium (Myfortic ® ) est une formulation gastroresistante de l’acide mycophenolique utilise comme agent immunosuppresseur. Nous rapportons le cas d’une femme ayant eu des ulcerations buccales multiples ass
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e205f404d7f2b6a19189a6360f7d2cb8
https://doi.org/10.1016/s0151-9638(07)92831-8
https://doi.org/10.1016/s0151-9638(07)92831-8
Publikováno v:
La Revue de Médecine Interne. 27:344-346
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b352f6a02c34884c31df4f10fc339970
https://doi.org/10.1016/j.revmed.2005.10.017
https://doi.org/10.1016/j.revmed.2005.10.017
Autor:
D, Thuillier, G, Chaby, A, Dadban, E, Dascotte, O, Miquel-Christophe, M, Andrejak, D, Chatelain, C, Lok
Publikováno v:
Annales de dermatologie et de venereologie. 136(10)
Heparin-induced bullous hemorrhagic dermatosis is a rare, recently described side-effect of subcutaneous heparin injection. We describe a patient simultaneously presenting distant haemorrhagic bullae and eczematous reaction at the low molecular-weigh
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9ba2eacad22275ba76c2701713f4e507
https://pubmed.ncbi.nlm.nih.gov/19801254
https://pubmed.ncbi.nlm.nih.gov/19801254
Publikováno v:
Annales de dermatologie et de venereologie. 134(11)
Mycophenolate sodium (Myfortic) is an enteric-coated formulation of the immunosuppressant therapy mycophenolic acid. We report a case of diffuse mouth ulceration in a patient treated with Myfortic presenting recurrence after another dose of drug.We r
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f865648dd7fade9c218f501efacf4a66
https://pubmed.ncbi.nlm.nih.gov/18033067
https://pubmed.ncbi.nlm.nih.gov/18033067
Publikováno v:
Archives des maladies du coeur et des vaisseaux. (1)
Although the year 2005 has reinforced the therapeutic advances of 2004, with confirmation of certain concepts, the 'coxib affair' has continued to provoke arguments between pharmaceutical companies, licensing agencies as well as patients, some of who
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a20ca2957547ea1bd4de35a057583c05
https://pubmed.ncbi.nlm.nih.gov/16479971
https://pubmed.ncbi.nlm.nih.gov/16479971
Publikováno v:
Archives des maladies du coeur et des vaisseaux.
The year 2004 was not marked by major pharmacological advances, but by confirmation of previous "evidence". Several innovative drugs for stable angina (ranolazine, ivabradine), some interesting results in acute coronary syndrome (PROVE IT study), som
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::638aaad4e7d8fb99de322b500ff2ea10
https://pubmed.ncbi.nlm.nih.gov/15714864
https://pubmed.ncbi.nlm.nih.gov/15714864
Autor:
G. Choukroun, J. C. Mazière, C. Tribouilloy, M. Andrejak, S. Kamel, M. Brazier, Ziad A. Massy, C. Mazière, Michel Slama
Publikováno v:
Pediatric nephrology (Berlin, Germany). 20(3)
Vascular and/or valvular calcifications in patients with chronic kidney disease (CKD) appear to indicate a poor prognosis in terms of overall survival and cardiovascular morbidity and mortality. Inflammation and oxidative stress represent new feature
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::340d4bee34327cfdd676cd22139d902d
https://pubmed.ncbi.nlm.nih.gov/15549414
https://pubmed.ncbi.nlm.nih.gov/15549414